Patents Examined by Kimberly Chong
  • Methods relating to lung cancer
    Patent number: 11426423
    Abstract: The methods and assays described herein relate to detection, diagnosis, and treatment of lung cancer, e.g., by detecting the level of expression of certain miRNAs described herein and/or by therapeutically increasing the level of those miRNAs.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: August 30, 2022
    Assignee: Trustees of Boston University
    Inventors: Ana Brandusa Pavel, Joshua David Campbell, Marc Elliott Lenburg, Avrum Elliot Spira
  • Modulation of Huntington expression
    Patent number: 11421231
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: August 23, 2022
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Compositions and methods for the systemic treatment of arthritis
    Patent number: 11406688
    Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: August 9, 2022
    Assignee: BAYLOR RESEARCH INSTITUTE
    Inventors: Jacques F. Banchereau, Maria Virginia Pascual
  • Adeno-associated virus vector delivery of microRNA-29 and micro-dystrophin to treat muscular dystrophy
    Patent number: 11406717
    Abstract: The invention provides for recombinant AAV vectors comprising a polynucleotide sequence comprising the guide strand of miR-29c and methods of using the recombinant vectors to reduce or prevent fibrosis in subjects suffering from dystrophinopathy or muscular dystrophy. The invention also provides for combination therapies comprising expressing both miR-29 and micro-dystrophin to reduce and prevent fibrosis in patients suffering from dystrophinopathy or muscular dystrophy.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: August 9, 2022
    Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
    Inventors: Louise Rodino-Klapac, Jerry R. Mendell, Kristin N. Heller
  • Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
    Patent number: 11408000
    Abstract: The present disclosure features useful compositions and methods to treat nucleotide repeat expansion disorders, e.g., in a subject in need thereof. In some aspects, the compositions and methods described herein are useful in the treatment of disorders associated with MSH3 activity.
    Type: Grant
    Filed: June 2, 2021
    Date of Patent: August 9, 2022
    Assignee: Triplet Therapeutics, Inc.
    Inventors: Nessan Anthony Bermingham, Brian R. Bettencourt, Pei Ge
  • Channel modulators
    Patent number: 11401516
    Abstract: The inventions relate to compositions and articles of manufacture comprising connexin modulators, pannexin modulators, gap junction modulators, hemichannel modulators, and pannexin channel modulators and their use, alone or in combination, in treating ocular and other disorders.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: August 2, 2022
    Assignees: AUCKLAND UNISERVICES LIMITED, OCUNEXUS THERAPEUTICS, INC.
    Inventors: Colin Richard Green, Yeri Kim, Anthony Phillips, Bradford James Duft
  • Nucleic acid-polypeptide compositions and methods of inducing exon skipping
    Patent number: 11400163
    Abstract: Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: August 2, 2022
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Arthur A. Levin, Andrew John Geall, Venkata Ramana Doppalapudi, Michael Caramian Cochran, Hanhua Huang, Rob Burke
  • RNA containing modified nucleosides and methods of use thereof
    Patent number: 11389547
    Abstract: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: July 19, 2022
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Katalin Kariko, Drew Weissman
  • CRISPR-related methods and compositions with governing gRNAS
    Patent number: 11390887
    Abstract: Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: July 19, 2022
    Assignees: Editas Medicine, Inc., The Broad Institute Inc., Massachusetts Institute of Technology, University of Iowa Research Foundation
    Inventors: Feng Zhang, Deborah Palestrant, Beverly Davidson, Jordi Mata-Fink, Edgardo Rodriguez, Alexis Borisy
  • Method for designing RIG-I ligands
    Patent number: 11382966
    Abstract: The present invention belongs to the field of biotechnology and pharmaceuticals. The present inventors found a sequence motif for identifying potent RIG-I agonists. Accordingly, the present invention is directed to a method for producing RIG-I agonists, the RIG-I agonists produced by said methods, and uses of said RIG-I agonists, as defined in the claims.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: July 12, 2022
    Assignee: Rigontec GmbH
    Inventors: Micha Feld, Christine Schuberth-Wagner
  • Compositions and methods of inhibiting gene expression in a lung
    Patent number: 11377657
    Abstract: The present invention provides compositions and methods for delivery to a lung tissue comprising a small interfering RNA (siRNA) capable of inhibiting expression of a gene, and a surfactant. In one aspect, a non-polymeric methods composition comprising a small interfering RNA (siRNA) capable of inhibiting expression of a gene, and a surfactant is disclosed. In other aspects, a method of inhibiting gene expression in a lung of a subject in need thereof and treating bronchopulmonary dysplasia in a lung of a subject also disclosed. The methods comprise administering a therapeutically effective amount of a non-polymeric composition to the lung of the subject, wherein the non-polymeric composition comprises a small interfering RNA (siRNA) capable of inhibiting expression of a gene, and a surfactant.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: July 5, 2022
    Inventor: Vineet Bhandari
  • Chemically modified messenger RNA's
    Patent number: 11377656
    Abstract: This invention provides messenger RNA (mRNA) molecules comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), (II), and (III), gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of mRNA molecules.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: July 5, 2022
    Assignee: Novartis AG
    Inventors: Shari Lynn Caplan, Katsumasa Nakajima
  • Nucleic acid-polypeptide compositions and uses thereof
    Patent number: 11364302
    Abstract: Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: June 21, 2022
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventors: Andrew John Geall, Venkata Ramana Doppalapudi, Joel Daniel Arias, David Sai-Ho Chu, Michael Caramian Cochran, Rob Burke, Philip Kovach, Barbora Malecova
  • Method for delivering RNA to neurons to treat herpes infections
    Patent number: 11351273
    Abstract: Aspects of the application relate to methods and compositions for delivering therapeutic nucleic acids to neural cells or tissue in a subject. Additional aspects of the application relate to therapeutic nucleic acids, for example therapeutic ribozymes, that are useful for inhibiting viral reactivation in a subject.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: June 7, 2022
    Assignees: Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College, University of Florida Research Foundation, Incorporated
    Inventors: David C. Bloom, Alfred S. Lewin, Donna M. Neumann, Zachary L. Watson, Sonal Sanjeev Tuli, Gregory Scott Schultz
  • Exon skipping oligomer conjugates for muscular dystrophy
    Patent number: 11338041
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: May 24, 2022
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Gunnar J. Hanson, Marco A. Passini, Frederick Joseph Schnell
  • Modified compounds and uses thereof
    Patent number: 11332733
    Abstract: The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: May 17, 2022
    Assignee: lonis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
  • Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (SCAP) inhibitors
    Patent number: 11331332
    Abstract: The present disclosure provides methods of treating subjects having increased lipid levels and/or increased triglyceride levels, methods of identifying subjects having an increased risk of developing an increased lipid level and/or increased triglyceride level, methods of detecting human Sterol Regulatory Element Binding Protein Cleavage-Activating Protein (SCAP) variant nucleic acid molecules and variant polypeptides, and SCAP variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: May 17, 2022
    Assignees: Regeneron Pharmaceuticals, Inc., University of Maryland, Baltimore
    Inventors: Da-Wei Gong, James A. Perry, Alan Shuldiner, Nehal Gosalia, Cristopher Van Hout
  • RNA nanoparticles for brain tumor treatment
    Patent number: 11325939
    Abstract: The presently-disclosed subject matter relates to an artificial RNA nanostructure molecule and method to treat brain tumor in a subject. More particularly, the presently disclosed subject matter relates to a RNA nanostructure containing a multiple branched RNA nanoparticle, a brain tumor targeting module, and an effective amount of a therapeutic agent. Further, the presently disclosed subject matter relates to a method of using the RNA nanostructure composition to treat brain tumor in a subject having or at risk of having brain tumor.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: May 10, 2022
    Assignee: University of Kentucky Research Foundation
    Inventors: Peixuan Guo, Carlo M. Croce, Tae Jin Lee, Farzin Haque, Hui Li
  • Formulation for administration of RNA
    Patent number: 11318195
    Abstract: The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine. The RNA may encode a protein of interest, such as a pharmaceutically active protein. Furthermore, the present invention relates to pharmaceutical products, comprising said RNA polyplex formulations for parenteral application to humans or to animals. The present invention relates as well to manufacturing of such pharmaceutical products, comprising, optionally, steps of sterile filtration, freezing and dehydration.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: May 3, 2022
    Assignees: BIONTECH SE, TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Heinrich Haas, Annette Vogel, Daniel Zucker, Stephanie Erbar, Kerstin Walzer, Anne Schlegel, Sebastian Hörner, Sebastian Kreiter, Mustafa Diken, Jorge Moreno Herrero
  • Nucleic acid inhibiting expression of the MEX3B gene, MEX3B gene expression inhibitor, method for inhibiting MEX3B gene expression, and prophylactic or therapeutic agent for disease caused by MEX3B gene expression
    Patent number: 11312956
    Abstract: A nucleic acid which can inhibit expression of the MEX3B gene with low cytotoxicity as a side effect, an MEX3B gene expression inhibitor which contains said nucleic acid, a method for inhibiting MEX3B gene expression, and a prophylactic or therapeutic agent for disease caused by MEX3B gene expression are provided. This nucleic acid, which inhibits the expression of the MEX3B gene, is an antisense oligonucleotide having a sequence complementary to an oligonucleotide that contains at least 10 contiguous nucleotides in an untranslated region in an exon of the MEX3B gene, or a double-stranded RNA including at least 20 contiguous nucleotides in the aforementioned untranslated region, or DNA encoding said double-stranded RNA.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: April 26, 2022
    Assignees: TAK-CIRCULATOR CO., LTD, UNIVERSITY OF TOKYO
    Inventors: Tetsu Akiyama, Yusuke Yamazumi, Kazuyoshi Kofu